Merz Aesthetics is expanding its U.S. BELOTERO® portfolio with the FDA approval of two new biomimetic hyaluronic acid (HA) dermal fillers: BELOTERO VOLUME® (+) and BELOTERO INTENSE® (+). Engineered using patented Cohesive Polydensified Matrix (CPM®) gel technology, these fillers integrate seamlessly into skin tissue to support facial balancing, natural expressions, and authentic movement.
Key Additions & Specifics
- BELOTERO VOLUME® (+)
- Indication: Mid-face volume loss and midface contour deficiencies in adults 22+.
- Performance: Features dual cross-linking technology for dynamic tissue integration. In clinical trials, 95% of patients reported satisfaction at 12 weeks, with results lasting up to 18 months.
- U.S. Availability: October 14, 2026.
- BELOTERO INTENSE® (+)
- Indication: Lip augmentation and improved lip fullness in adults over 21.
- Performance: Maintains natural lip movement in high-expression areas. Clinical trials showed 100% patient satisfaction, with results lasting up to 12 months.
- U.S. Availability: December 1, 2026.
- BELOTERO BALANCE® (+)
- Indication: Pre-existing product for smoothing moderate-to-severe facial wrinkles and folds (e.g., nasolabial folds, perioral lines, infraorbital hollows).
- Performance: FDA-cleared in 2021, featuring up to 18-month durability and 98% patient satisfaction.
Market Context
Driven by strong consumer demand—where 74% of patients prefer natural aesthetic enhancements over dramatic transformations—this expanded lineup gives healthcare providers a single, cohesive HA portfolio tailored to individualized facial restoration plans.
Leave a Reply